These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35972377)

  • 1. Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism.
    Hesse F; Wright AJ; Somai V; Bulat F; Kreis F; Brindle KM
    Cancer Res; 2022 Oct; 82(19):3622-3633. PubMed ID: 35972377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deuterium Metabolic Imaging Differentiates Glioblastoma Metabolic Subtypes and Detects Early Response to Chemoradiotherapy.
    Low JCM; Cao J; Hesse F; Wright AJ; Tsyben A; Alshamleh I; Mair R; Brindle KM
    Cancer Res; 2024 Jun; 84(12):1996-2008. PubMed ID: 38635885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring tumor cell death in murine tumor models using deuterium magnetic resonance spectroscopy and spectroscopic imaging.
    Hesse F; Somai V; Kreis F; Bulat F; Wright AJ; Brindle KM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33727417
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of the sensitivity of
    Hesse F; Wright A; Bulat F; Kreis F; Brindle KM
    NMR Biomed; 2023 Oct; 36(10):e4965. PubMed ID: 37148156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
    Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy.
    Bohndiek SE; Kettunen MI; Hu DE; Witney TH; Kennedy BW; Gallagher FA; Brindle KM
    Mol Cancer Ther; 2010 Dec; 9(12):3278-88. PubMed ID: 21159611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deuterium MRSI of tumor cell death in vivo following oral delivery of
    Hesse F; Wright AJ; Bulat F; Somai V; Kreis F; Brindle KM
    Magn Reson Med; 2022 Nov; 88(5):2014-2020. PubMed ID: 35816502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.
    Mignion L; Dutta P; Martinez GV; Foroutan P; Gillies RJ; Jordan BF
    Cancer Res; 2014 Feb; 74(3):686-94. PubMed ID: 24285723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
    Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
    Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
    Kerkhof M; Tans PL; Hagenbeek RE; Lycklama À Nijeholt GJ; Holla FK; Postma TJ; Straathof CS; Dirven L; Taphoorn MJ; Vos MJ
    CNS Oncol; 2017 Oct; 6(4):297-306. PubMed ID: 28984142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Brain Imaging Collaboration Suite (BrICS): A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow.
    Gurbani S; Weinberg B; Cooper L; Mellon E; Schreibmann E; Sheriff S; Maudsley A; Goryawala M; Shu HK; Shim H
    Tomography; 2019 Mar; 5(1):184-191. PubMed ID: 30854456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperpolarized [1,4-
    Miller JJ; Lau AZ; Nielsen PM; McMullen-Klein G; Lewis AJ; Jespersen NR; Ball V; Gallagher FA; Carr CA; Laustsen C; Bøtker HE; Tyler DJ; Schroeder MA
    JACC Cardiovasc Imaging; 2018 Nov; 11(11):1594-1606. PubMed ID: 29248653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors.
    Gallagher FA; Kettunen MI; Hu DE; Jensen PR; Zandt RI; Karlsson M; Gisselsson A; Nelson SK; Witney TH; Bohndiek SE; Hansson G; Peitersen T; Lerche MH; Brindle KM
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19801-6. PubMed ID: 19903889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Shiroishi MS; Boxerman JL; Pope WB
    Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance.
    Salzillo TC; Mawoneke V; Weygand J; Shetty A; Gumin J; Zacharias NM; Gammon ST; Piwnica-Worms D; Fuller GN; Logothetis CJ; Lang FF; Bhattacharya PK
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685601
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.